Sterile-device submission evidence: process validation and pyrogen questions
The acquired January 2024 FDA guidance distinguishes established and novel sterilization methods, then describes information for devices labelled sterile, including validation, residues and pyrogenicity where relevant. Choose the work from the actual process, device and claim. A product name does not select a validated process.
Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.
Sourced criteria · US
What changes the service scope?
Decision or task
What the source describes
What to prepare
Does this guidance cover the process?
Its scope concerns 510(k) devices labelled sterile and industrial terminal sterilization based on microbial inactivation, with stated exclusions. [1]
Record process, sterile claim and submission context; distinguish healthcare reprocessing, aseptic processing and other excluded tasks.
Is the method established or novel in the cited context?
The guidance distinguishes method categories and describes novel processes. [2]
Document the exact process, modifications and evidence; ask the specialist to assess the category under the current source rather than assuming familiar chemicals settle it.
What validation and residue information is needed?
The guidance discusses cycle-validation method, sterilization site, relevant radiation dose and chemical-sterilant residue information. [3]
Agree validation deliverables and relevant residue evaluation for the actual device/contact; do not invent an acceptable limit or successful validation.
What is the pyrogenicity claim and evidence?
The guidance discusses chosen pyrogen/endotoxin methods and limits, batch or sampling information and the related rationale. [4]
Separate bacterial endotoxin and material-mediated pyrogen questions; review the claim, contact and method/limit rationale with the specialist.
FDA guidance recommendations are distinct from binding requirements. Device-specific limits, method category, complete microbiology evidence and current standard recognition remain unresolved. This page does not validate a process or certify sterility.
A scoped evidence and handoff plan
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
Does this guidance cover the process?
Record process, sterile claim and submission context; distinguish healthcare reprocessing, aseptic processing and other excluded tasks.
Useful evidence: Device/claim/process description and scope/exclusion assessment.
Is the method established or novel in the cited context?
Document the exact process, modifications and evidence; ask the specialist to assess the category under the current source rather than assuming familiar chemicals settle it.
Useful evidence: Process/site specification, change description and category rationale.
What validation and residue information is needed?
Agree validation deliverables and relevant residue evaluation for the actual device/contact; do not invent an acceptable limit or successful validation.
Useful evidence: Validation plan/method, device/process parameters, site and relevant residue evidence.
What is the pyrogenicity claim and evidence?
Separate bacterial endotoxin and material-mediated pyrogen questions; review the claim, contact and method/limit rationale with the specialist.
Useful evidence: Label claim, method/limit rationale and release/sampling plan.
Work packages and dependencies
Conditional: Process-specific validation, residue and microbiology evidence plan — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Optional: Separate sterile-barrier evidence and package task — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Questions for providers
Which exact actor, product or processing facts support the quoted scope, and what is still unresolved?
How will the listed records reach the responsible people, and who owns each change or authority request?
Which tasks and entities are excluded from the agreement, and which additional services need a separate assessment?
Sources and data dates
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.
